A U.S. cannabis company, Curaleaf Holdings Inc., has made a bid to acquire Aurora Cannabis Inc., based in Edmonton. Aurora has announced the formation of a special committee to review the unsolicited offer. Curaleaf aims to create a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets.
Despite multiple attempts to privately negotiate with Aurora’s leadership, Curaleaf decided to publicly disclose its proposal after receiving no engagement from Aurora’s board following a formal letter of intent sent on June 23. Curaleaf expressed disappointment in Aurora’s lack of constructive discussions and plans to directly engage with Aurora’s shareholders.
Curaleaf proposed to pay Aurora shareholders $4 US per share, along with an additional $0.75 US cash for each share. While Aurora confirmed receiving letters from Curaleaf, it denied the claim that it refused to consider the offer. Aurora’s independent director had ongoing correspondence with Curaleaf’s CEO as of July 24.
Aurora will convene a special committee to evaluate the proposal’s alignment with stakeholder interests. The company emphasized that there is no guarantee of a deal and that its operations will continue as usual. Analysts caution that Curaleaf’s offer undervalues Aurora’s long-term potential and market position in the medical cannabis sector.
Curaleaf believes that merging with Aurora would leverage its global distribution network with Aurora’s strong international medical cannabis presence, cultivation capabilities, and manufacturing capacity. The companies collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf expecting annual cost synergies of at least $40 million US from the acquisition. Curaleaf views the merger as beneficial for both companies’ shareholders, offering exposure to a more diversified global platform and U.S. regulatory opportunities.